دورية أكاديمية
Tick-borne encephalitis vaccine effectiveness and barriers to vaccination in Germany.
| العنوان: | Tick-borne encephalitis vaccine effectiveness and barriers to vaccination in Germany. |
|---|---|
| المؤلفون: | Nygren TM; Immunisation Unit, Robert Koch Institute, Seestraße 10, 13353, Berlin, Germany. NygrenT@rki.de.; Charité - Universitätsmedizin Berlin, Berlin, Germany. NygrenT@rki.de., Pilic A; Immunisation Unit, Robert Koch Institute, Seestraße 10, 13353, Berlin, Germany., Böhmer MM; Bavarian Health and Food Safety Authority (LGL), Oberschleißheim, Germany.; Institute of Social Medicine and Health Systems Research, Otto-Von-Guericke-University Magdeburg, Magdeburg, Germany., Wagner-Wiening C; State Health Office Baden-Wuerttemberg (LGA), Stuttgart, Germany., Wichmann O; Immunisation Unit, Robert Koch Institute, Seestraße 10, 13353, Berlin, Germany., Harder T; Immunisation Unit, Robert Koch Institute, Seestraße 10, 13353, Berlin, Germany., Hellenbrand W; Immunisation Unit, Robert Koch Institute, Seestraße 10, 13353, Berlin, Germany. |
| المصدر: | Scientific reports [Sci Rep] 2022 Jul 09; Vol. 12 (1), pp. 11706. Date of Electronic Publication: 2022 Jul 09. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: London : Nature Publishing Group, copyright 2011- |
| مواضيع طبية MeSH: | Encephalitis, Tick-Borne*/epidemiology , Encephalitis, Tick-Borne*/prevention & control , Viral Vaccines*, Case-Control Studies ; Germany/epidemiology ; Humans ; Vaccination ; Vaccine Efficacy |
| مستخلص: | Tick-borne encephalitis (TBE) vaccination coverage remains low in Germany. Our case-control study (2018-2020) aimed to examine reasons for low vaccine uptake, vaccine effectiveness (VE), and vaccine breakthrough infections (VBIs). Telephone interviews (581 cases, 975 matched controls) covered vaccinations, vaccination barriers, and confounders identified with directed acyclic graphs. Multivariable logistic regression determined VE as 1-odds ratio with 95% confidence intervals (CI). We additionally calculated VE with the Screening method using routine surveillance and vaccination coverage data. Main vaccination barriers were poor risk perception and fear of adverse events. VE was 96.6% (95% CI 93.7-98.2) for ≥ 3 doses and manufacturer-recommended dosing intervals. Without boosters, VE after ≥ 3 doses at ≤ 10 years was 91.2% (95% CI 82.7-95.6). VE was similar for homologous/heterologous vaccination. Utilising routine surveillance data, VE was comparable (≥ 3 doses: 92.8%). VBIs (n = 17, 2.9% of cases) were older, had more comorbidities and higher severity than unvaccinated cases. However, only few VBIs were diagnostically confirmed; 57% of re-tested vaccinated cases (≥ 1 dose, n = 54) proved false positive. To increase TBE vaccine uptake, communication efforts should address complacency and increase confidence in the vaccines' safety. The observed duration of high VE may inform decision-makers to consider extending booster intervals to 10 years. (© 2022. The Author(s).) |
| التعليقات: | Erratum in: Sci Rep. 2024 Jan 30;14(1):2504. (PMID: 38291240) |
| References: | Stroke. 2011 Aug;42(8):2276-9. (PMID: 21680905) J Travel Med. 2022 Mar 21;29(2):. (PMID: 34581402) Ticks Tick Borne Dis. 2018 May;9(4):768-777. (PMID: 29501619) J Infect. 2023 Apr;86(4):369-375. (PMID: 36796679) Vaccine. 2015 Aug 14;33(34):4161-4. (PMID: 25896383) Antiviral Res. 2003 Jan;57(1-2):129-46. (PMID: 12615309) Expert Rev Vaccines. 2006 Aug;5(4):461-6. (PMID: 16989626) Expert Rev Vaccines. 2005 Oct;4(5):747-55. (PMID: 16221075) Vaccine. 2017 Jun 5;35(25):3295-3302. (PMID: 28442231) Int J Epidemiol. 1993 Aug;22(4):742-6. (PMID: 8225751) Ticks Tick Borne Dis. 2021 Sep;12(5):101779. (PMID: 34298356) Eur J Clin Microbiol Infect Dis. 1992 Oct;11(10):894-900. (PMID: 1486884) J Infect Dis. 2023 Feb 14;227(4):512-521. (PMID: 35235953) Int J Epidemiol. 2016 Dec 1;45(6):1887-1894. (PMID: 28089956) Ticks Tick Borne Dis. 2018 May;9(4):882-888. (PMID: 29576392) Clin Microbiol Infect. 2020 Aug;26(8):1090.e7-1090.e13. (PMID: 31843655) Microorganisms. 2022 Mar 23;10(4):. (PMID: 35456742) J Travel Med. 2022 Mar 21;29(2):. (PMID: 34999897) Vaccines (Basel). 2020 Aug 12;8(3):. (PMID: 32806696) Vaccine. 2019 Jul 26;37(32):4623-4629. (PMID: 29397225) Vaccine. 2003 Apr 1;21 Suppl 1:S50-5. (PMID: 12628814) Expert Rev Mol Med. 2008 May 12;10:e12. (PMID: 18471342) Travel Med Infect Dis. 2020 Sep - Oct;37:101876. (PMID: 32931931) Vaccine. 2015 Sep 11;33(38):4962-8. (PMID: 26207593) Vaccine. 2007 Oct 23;25(43):7559-67. (PMID: 17869389) Ticks Tick Borne Dis. 2017 Oct;8(6):872-877. (PMID: 28778675) J Intern Med. 2017 Aug;282(2):142-155. (PMID: 28440879) J Clin Microbiol. 2020 Mar 25;58(4):. (PMID: 31969423) World J Clin Cases. 2015 May 16;3(5):430-41. (PMID: 25984517) Vaccine. 2022 Jan 31;40(5):819-825. (PMID: 34952753) Vaccine. 2021 Jan 29;39(5):830-838. (PMID: 33414049) |
| المشرفين على المادة: | 0 (Viral Vaccines) |
| تواريخ الأحداث: | Date Created: 20220709 Date Completed: 20220712 Latest Revision: 20240201 |
| رمز التحديث: | 20240201 |
| مُعرف محوري في PubMed: | PMC9271034 |
| DOI: | 10.1038/s41598-022-15447-5 |
| PMID: | 35810184 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder كن أول من يترك تعليقا!